Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A PHASE2 clinical study on Unresectable Hepatocellular Carcinoma, this trial is completed. The trial is conducted by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jan 2024 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Oct 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Avellino, Italy , Benevento, Italy , Bologna, Italy , Brussels, Belgium , Essen, Germany , Frankfurt am Main, Germany , Galveston, United States , Ghent, Belgium , Hamburg, Germany , Los Angeles, United States and 11 more locations